The Magazine for Sleep Professionals
Tuesday, September 29, 2026
Sleep Specialists, LLC (DBA 2Z Medical) announces that Zzoma is now covered by a growing number of leading health insurance providers. This expanded coverage significantly increases access to this innovative, mask-free treatment option for individuals with positional OSA across the United States. Zzoma is an FDA-cleared positional therapy device indicated […]
While continuous positive airway pressure (CPAP) is still the gold standard treatment for obstructive sleep apnea (OSA), it is well-established that many patients struggle with long-term adherence and tolerance.1 The literature indicates that CPAP non-compliance rates remain as high as 34% with little improvement over the last two decades.2 As […]
EnsoData and Nonin partner to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2® Model 3150 reusable wrist-worn device, offering sleep labs an […]
Incannex Healthcare Inc., a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). IHL-42X is the Company’s […]
IntelliPAP™ is a new optional tool for physicians to use in noninvasive ventilation for patients with respiratory insufficiency and obstructive sleep apnea (OSA). This innovative device automatically adjusts the positive end-expiratory pressure (PEEP) levels in response to sleep-disordered breathing (SDB) events. To enhance safety, clinicians can set minimum and maximum […]
ZOLL® has announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for heart failure (HF) patients with central sleep apnea (CSA). The analysis was performed post-hoc using a hierarchical endpoint comprised of mortality, HF hospitalization, and health status. The new analysis was […]
Nyxoah SA has announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis. The DREAM study is a pivotal trial being conducted under an investigational device exemption […]
It’s well understood and accepted that sleep position, in particular the supine position in which a person sleeps on their back with their face and abdomen facing upwards, is associated with an increase in sleep-disordered breathing.1 While over half of all cases of obstructive sleep apnea (OSA) are classified as […]
As the prevalence of atrial fibrillation (AF) continues to rise, particularly among the aging population, its connection with obstructive sleep apnea (OSA) has become increasingly evident.1 Patients with AF seeking treatment for OSA often present with a complex medical history that includes a number of comorbidities, such as hypertension, acid […]
EnsoData, a pioneer in healthcare AI, achieved FDA 510(k) clearance for groundbreaking technology that enables AI-powered sleep diagnosis using FDA-cleared pulse oximetry (pulse ox) devices. Powered by EnsoSleep PPG scoring, widely available and wearable pulse ox technology can be deployed for a high-quality, accessible, and cost-effective approach to diagnosing sleep […]
